OBJECTIVE: To assess prospectively progression and relationship of hallucinations and sleep disorders over a 10-year longitudinal study of patients with Parkinson disease (PD). METHODS:Eighty-nine patients with PD were recruited to fill cells of normal sleep without hallucinations (n = 20), sleep fragmentation only (n = 20), vivid dreams/nightmares (n = 20), hallucinations with insight (n = 20), and hallucinations without insight (n = 9). At baseline, 0.5, 1.5, 4, 6, and 10 years, sleep disorders and hallucinations were assessed by standardized scales with the longitudinal data analyzed by generalized estimating equations with assumptions of linearity in time. RESULTS: At 10 years, we could account for all subjects (27 interviewed, 61 deceased, and 1 too ill for interview). Hallucination prevalence and severity increased over time (p < 0.0001, p = 0.0001). Acting out dreams also increased over time (p = 0.001). In contrast, presence of vivid dreams/nightmares or sleep fragmentation did not increase over time. For all visits, the prevalence of sleep fragmentation did not differ between subjects with vs without hallucinations (odds ratio [OR] = 1.50, p = 0.09). However, severe sleep fragmentation was associated with concurrent hallucinations (OR 2.01, p = 0.006). The presence of hallucinations was also highly associated with concurrent vivid dreams/nightmares (OR = 2.60, p < 0.0001) and with concurrent acting out dreams (OR = 2.38, p = 0.0004). Among the baseline nonhallucinators, no sleep abnormalities at study entry predicted future development of hallucinations. CONCLUSIONS:Hallucinations and sleep abnormalities follow very different patterns of progression in PD over 10 years. Whereas patients with hallucinations often have concurrent sleep aberrations, no sleep problem is predictive of future hallucinations.
RCT Entities:
OBJECTIVE: To assess prospectively progression and relationship of hallucinations and sleep disorders over a 10-year longitudinal study of patients with Parkinson disease (PD). METHODS: Eighty-nine patients with PD were recruited to fill cells of normal sleep without hallucinations (n = 20), sleep fragmentation only (n = 20), vivid dreams/nightmares (n = 20), hallucinations with insight (n = 20), and hallucinations without insight (n = 9). At baseline, 0.5, 1.5, 4, 6, and 10 years, sleep disorders and hallucinations were assessed by standardized scales with the longitudinal data analyzed by generalized estimating equations with assumptions of linearity in time. RESULTS: At 10 years, we could account for all subjects (27 interviewed, 61 deceased, and 1 too ill for interview). Hallucination prevalence and severity increased over time (p < 0.0001, p = 0.0001). Acting out dreams also increased over time (p = 0.001). In contrast, presence of vivid dreams/nightmares or sleep fragmentation did not increase over time. For all visits, the prevalence of sleep fragmentation did not differ between subjects with vs without hallucinations (odds ratio [OR] = 1.50, p = 0.09). However, severe sleep fragmentation was associated with concurrent hallucinations (OR 2.01, p = 0.006). The presence of hallucinations was also highly associated with concurrent vivid dreams/nightmares (OR = 2.60, p < 0.0001) and with concurrent acting out dreams (OR = 2.38, p = 0.0004). Among the baseline nonhallucinators, no sleep abnormalities at study entry predicted future development of hallucinations. CONCLUSIONS:Hallucinations and sleep abnormalities follow very different patterns of progression in PD over 10 years. Whereas patients with hallucinations often have concurrent sleep aberrations, no sleep problem is predictive of future hallucinations.
Authors: Elin B Forsaa; Jan Petter Larsen; Tore Wentzel-Larsen; Christopher G Goetz; Glenn T Stebbins; Dag Aarsland; Guido Alves Journal: Arch Neurol Date: 2010-08
Authors: Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris Journal: Mov Disord Date: 2008-04-30 Impact factor: 10.338
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Stewart A Factor; N Kyle Steenland; Donald S Higgins; Eric S Molho; Denise M Kay; Jennifer Montimurro; Ami R Rosen; Cyrus P Zabetian; Haydeh Payami Journal: Mov Disord Date: 2011-06-28 Impact factor: 10.338
Authors: Daniel Weintraub; Nicole Dietz; John E Duda; David A Wolk; Jimit Doshi; Sharon X Xie; Christos Davatzikos; Christopher M Clark; Andrew Siderowf Journal: Brain Date: 2011-11-21 Impact factor: 13.501
Authors: Julie M Hall; Claire O'Callaghan; James M Shine; Alana J Muller; Joseph R Phillips; Courtney C Walton; Simon J G Lewis; Ahmed A Moustafa Journal: J Neural Transm (Vienna) Date: 2016-03-03 Impact factor: 3.575
Authors: Pablo Martinez-Martin; John B Wetmore; Carmen Rodríguez-Blázquez; Tomoko Arakaki; Oscar Bernal; Victor Campos-Arillo; Christopher Cerda; Ingrid Estrada-Bellmann; Nélida Garretto; Letty Ginsburg; Jorge Uriel Máñez-Miró; Juan Carlos Martínez-Castrillo; Ivonne Pedroso; Marcos Serrano-Dueñas; Carlos Singer; Mayela Rodríguez-Violante; Francisco Vivancos Journal: Mov Disord Clin Pract Date: 2019-03-18